Data values are presented in mean ± SD collected from three animals. For experimental design refer to Section 2.4. Saline (0.9% NaCl) was used as vehicle. *: Significantly decreased compared to vehicle group (p < 0.05). Table S2 : Renal clearance of CP-I and CP-III following i.v injection of vehicle or modulator.
Dose group
Modulator dose (mg/kg, i.v) Renal clearance # (ml/min) CP-I CP-III Vehicle -0.8 ± 0.2 2.3 ± 2.3 Mitoxantrone 6 0.9 ± 0.6 3.9 ± 3.9 Vehicle -1.5 ± 0.4 6.3 ± 7.1 Mitoxantrone 15 5.6 ± 4.1 27 ± 23 Vehicle -1.3 ± 0.6 3.4 ± 0.3 Progesterone 1 2.4 ± 1.4 6.8 ± 3.7 Vehicle -1.5 ± 1.5 2.9 ± 2.2 Verapamil 10 0.3 ± 0.04 1.2 ± 0.9
All data values are presented in Mean ± SD, collected from three animal. For experimental design refer to Section 2.4. Saline (0.9% NaCl) was used as vehicle. 
All data values are presented in Mean ± SD, collected from three animal. For experimental design refer to Section 2.4. Saline (0.9% NaCl) was used as vehicle.
Figure S1: CP-I uptake was performed using silicon oil method. CP-I was tested at 0.5 µ M at 37 °C with and without rifamycin SV at 1mM. Samples were collected at 0.25, 1, 1.5 and 5 min. Hepatocyte accumulation of CP-I was analyzed by LC-MS/MS analysis. Figure S2 : Structures of the modulators (mitoxantrone, progesterone, testosterone and verapamil) used in this study, along with conventional probe substrate of MRP/Mrp2, estradiol β-glucuronide.
